PLUS1
3.13
0.01 (0.32%)
0.01 (0.32%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.06 | -1.89% | 3.12 | 3.02 | 3.20 | 3.20 | 3.18 | 17:47:20 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 3.12 | 3.18 | 0.06 | 1.89% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,370 | 945,656 | $ 3.11 | $ 2,944,183 | 1,927,454 | 0.231 - 7.03 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:49:05 | 60 | $ 3.13 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 120.33M | 38.57M | 37.95M | $ - | $ - | -0.66 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 7/01/2020 | 16:40 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 6/29/2020 | 08:16 | Business Wire | Genprex Added to Russell 3000® Index |
| 6/25/2020 | 08:17 | Business Wire | Genprex Receives USAN Approval of Non-Proprietary Name for.. |
| 6/24/2020 | 08:16 | Business Wire | Genprex CEO to Interview Live on “The Big Biz Show” |
| 6/23/2020 | 16:33 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/16/2020 | 08:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/16/2020 | 08:17 | Business Wire | Genprex Expands Manufacturing Program with Aldevron to.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.08 | 3.32 | 3.01 | 3.13 | 999,070 | 0.04 | 1.3% |
| 1 Month | 2.90 | 3.88 | 2.76 | 3.18 | 1,661,048 | 0.22 | 7.59% |
| 3 Months | 2.19 | 4.55 | 1.95 | 3.15 | 2,671,262 | 0.93 | 42.47% |
| 6 Months | 0.36 | 7.03 | 0.3111 | 3.05 | 5,149,325 | 2.76 | 766.67% |
| 1 Year | 1.11 | 7.03 | 0.231 | 2.88 | 2,748,297 | 2.01 | 181.08% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.13 | 1,281,447 | -1.57 | -33.48% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.13 | 1,281,447 | -1.57 | -33.48% |
Genprex Description
| Genprex Inc is a clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
